Relevant bibliographies by topics / Rehab Basel (Basel, Switzerland)

Academic literature on the topic 'Rehab Basel (Basel, Switzerland)'

Author: Grafiati
Published: 26 July 2024
Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rehab Basel (Basel, Switzerland).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Rehab Basel (Basel, Switzerland)"

1

Okujava, Rusudan, Fernando Garcia-Alcalde, Andreas Haldimann, Claudia Zampaloni, Ian Morrissey, Sophie Magnet, Nimmi Kothari, Ian Harding, and Kenneth Bradley. "1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017." Open Forum Infectious Diseases 5, suppl_1 (November 2018): S416. http://dx.doi.org/10.1093/ofid/ofy210.1190.

Full text
Abstract:
Abstract Background Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation. NAC restores and extends the activity of β-lactam antibiotics, such as meropenem (MEM), when used in combination against a variety of carbapenem-resistant Enterobacteriaceae (CRE). The first year results of the ROSCO surveillance study for MEM/NAC against contemporary clinical isolates are presented here. Methods Isolates (n = 4,695) collected in 2017 from 50 sites in the United States and European hospitals included 30 different species of Enterobacteriaceae (EB, n = 3,306), Pseudomonas spp. (n = 960) and Acinetobacter spp. (n = 429). The predominant species of EB are shown in figure below. MICs were determined by broth microdilution following CLSI methodology for MEM/NAC at a fixed 1:1 ratio (w:w) and by titrating MEM with a constant concentration of NAC at 4 mg/L. Results were compared with MIC values of MEM and NAC alone and standard of care antibiotics, including ceftazidime/avibactam (CAZ/AVI). Results MIC50/90 for MEM, NAC, and MEM/NAC against all EB isolates and by species are shown in the figure below. NAC alone displayed a bimodal MIC distribution for EB, with a prominent separation at ≤4 mg/L. MEM/NAC 1:1 inhibited 99.5, 99.7, and 99.9% of the 3,306 EB isolates tested, at ≤2, ≤4, and ≤8 mg/L, respectively; while MEM inhibited 96.5, 96.8, and 97.3% of the isolates at the same concentrations. Of 117 (3.5% of total EB) MEM nonsusceptible (by EUCAST) and multidrug resistant (MDR, by Magiorakos AP, et al., 2012) EB, 87.2, 92.3, and 96.6% were inhibited by MEM/NAC 1:1 at ≤2, ≤4, and ≤8 mg/L, respectively. Additionally, MEM/NAC1:1 displayed MIC ≤8 mg/L for 33 out of 37 CAZ/AVI-resistant MDR EB isolates. MEM/NAC had a similar activity to MEM alone against Pseudomonas spp. and Acinetobacter spp. Conclusion MEM/NAC combination shows excellent in vitro activity against current clinical EB isolates and the potential to extend MEM activity to MDR, MEM nonsusceptible and CAZ/AVI-resistant isolates, which supports the continued clinical development of MEM/NAC for infections caused by CREs. This project has been funded in part under HHS BARDA Contract HHSO100201600038C. Disclosures R. Okujava, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. F. Garcia-Alcalde, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. A. Haldimann, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. C. Zampaloni, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. I. Morrissey, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. S. Magnet, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. N. Kothari, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. I. Harding, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to Micron. K. Bradley, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary.
APA, Harvard, Vancouver, ISO, and other styles
2

YOSHIKAWA, Genki. "Two Years in Basel, Switzerland." Hyomen Kagaku 34, no. 2 (2013): 92–93. http://dx.doi.org/10.1380/jsssj.34.92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gewin, Virginia. "Erich Nigg, director of the Biozentrum, University of Basel, Basel, Switzerland." Nature 456, no. 7221 (November 2008): 542. http://dx.doi.org/10.1038/nj7221-542a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fromm, Katharina M., and Jürg Schefer. "European Crystallographic Meeting in Basel, Switzerland." Neutron News 28, no. 2 (April 3, 2017): 4–5. http://dx.doi.org/10.1080/10448632.2017.1307064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Willi, Patrik O., Dominic T. Egger, and Chantal S. Balmer. "Switzerland at the International Chemistry Olympiad 2022." CHIMIA 76, no. 10 (October 26, 2022): 876. http://dx.doi.org/10.2533/chimia.2022.876.

Full text
Abstract:
At the remote International Chemistry Olympiad 2022 hosted by China, two outstanding students from Switzerland won one bronze medal and one honorable mention. A joint remote participation to the event of the delegations from Germany, Austria, and Switzerland could be realized in Basel with the support of the University of Basel. The International Chemistry Olympiad 2023 will be hosted at ETH Zurich. This itinerary will mark the first time this annual event comes to Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
6

Brugnara, Carlo, Anja Harmeier, Lucia De Franceschi, Alessandro Matte, Michael Winter, Annette Koerner, Omar Khwaja, et al. "A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia." Blood 128, no. 22 (December 2, 2016): 1284. http://dx.doi.org/10.1182/blood.v128.22.1284.1284.

Full text
Abstract:
Abstract The unbalanced hemoglobin chain synthesis in beta-thalassemias leads to hemichrome-induced damage that contributes to ineffective erythropoiesis, hemolysis and reduced red cell survival. Iron overload related to ineffective erythropoiesis and abnormally low Hepcidin (Hamp), combined with the cytotoxic effects of free heme with free-alpha-chains play a key role in the increased generation of reactive oxygen species (ROS) in beta thalassemias.[2][HA{3] Here we used a specific and selective inhibitor of the plasma membrane expressed glycine transporter GlyT1 (Ro4917838). Use of Ro4917838 has been associated with a dose-dependent decrease in MCH, Hb, soluble transferrin receptor, and increase in absolute reticulocytes and RBC counts in several animal species, attributed to reduce glycine bioavailability in erythroblasts and decreased heme synthesis. In rats, Ro4917838 reduces heme synthesis, and down-regulates erythroid transferrin receptor, but does not interfere with hepcidin regulation and systemic iron homeostasis (Winter et al. Exp Hematol, DOI: 10.1016/j.exphem.2016.07.003). We aimed to determine if reduced cellular availability of glycine in erythroblasts may reduce heme synthesis, and impact pathologic erythropoiesis in a mouse model for b-thalassemia. Wild-type control (WT) C57B6/2J, and beta-thalassemia Hbbth3/+ mice were treated with either vehicle or Ro4917838 at dosages of 3, 10, 30 mg/kg/d administered over 4 weeks once daily by gavage. [6]RO4917838 administration was associated with significant improvements of central hallmarks of the b-thalassemia pathology. Reduced erythrocyte destruction was seen bydemonstrated by [8][WM{9]as significant improvements in erythrocyte morphology and amelioration of hemoglobin reduction in reticulocytes. We also observed an impressively quick reduction of the circulating erythroblast count within 1 week of initiating treatment. This was also associated with decreased hemolysis biomarkers. Ro4917838 induced a significant reduction in extramedullary erythropoiesis and reduction in orthochromatic erythroblasts as well as insoluble alpha chain aggregates in circulating red cells. Red cell survival of b-thal mice treated with 30 mg/kg/day Ro4917838 significantly increased by more than 50%. CD71+ erythroid precursors significantly decreased in WT mice treated with Ro4917838 at 30 mg/kg and in b-thal mice at the dosage of 30 mg/kg/ d. [10]These data suggest that Ro4917838 ameliorates anemia in a b-thalassemia mouse model and positively affects ineffective erythropoiesis and red cell survival in peripheral circulation. Ro4917838 may represent a novel therapeutic approach for the treatment of anemia in b-thalassemia patients. [1] I do see the point for beta-thalassemia, but this does not apply for all thalassemias, I mean the free alpha chains. The ROS yes, they have in common. In this sentence it seems to be that the alpha chains are culprit for ROS in all thalassemias. [HA{3]I do see the point for beta-thalassemia, but this does not apply for all thalassemias, I mean the free alpha chains. The ROS yes, they have in common. In this sentence it seems to be that the alpha chains are culprit for ROS in all thalassemias. ROS was not measured, therefore I would refrain mentioning it. No data is shown. [HA{5]ROS was not measured, therefore I would refrain mentioning it. No data is shown. I propose deletion of the PK info. Although the information is correct I don't think this is the level of detail needed for the abstract. It may even be confusing as it is not the focus of the abstract to do a cross species comparison. [AK7]I propose deletion of the PK info. Although the information is correct I don't think this is the level of detail needed for the abstract. It may even be confusing as it is not the focus of the abstract to do a cross species comparison. Dosing and dosing frequency is already described above, we do not need to repeat this here. [WM{9]Dosing and dosing frequency is already described above, we do not need to repeat this here. Was the liver expression determined or the serum Hepcidin levels measured? I would rephrase it if latter is the case. [HA{11]Was the liver expression determined or the serum Hepcidin levels measured? I would rephrase it if latter is the case. Disclosures Brugnara: F. Hoffmann-La Roche Ltd, Basel, Switzerland: Consultancy. Harmeier:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. De Franceschi:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Matte:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Winter:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Koerner:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Khwaja:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Singer:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Beneduce:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Federti:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Siciliano:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
7

Podavka, Ondřej. "Ladislav Velen of Žerotín and his Study Stay in Switzerland." AUC HISTORIA UNIVERSITATIS CAROLINAE PRAGENSIS 63, no. 1 (February 14, 2024): 203–12. http://dx.doi.org/10.14712/23365730.2023.30.

Full text
Abstract:
This contribution focuses on Ladislav Velen of Žerotín, member of an important Moravian family, and his stay in Basel between April 1592 and December 1593. His experiences from that time are described in Žerotín’s Itinerarium, which he wrote in 1589‒1594. After presenting some introductory information about this literary source and its writer, the author investigates contacts which Žerotín established during his studies in Basel, events he describes in the Itinerarium, and trips from Basel, which belong to the most detailed records in this diary. They depict his impression of the places he visited ‒ be it military facilities, ecclesiastic buildings, workshops, or other objects – but also the surrounding landscape and unforeseen events Žerotín encountered during his travels.
APA, Harvard, Vancouver, ISO, and other styles
8

Nickel, CHl. "Exploring the value of routinely measured hematology parameters for identification of elderly patients at high risk of death at the Emergency Department." Acute Medicine Journal 17, no. 4 (October 1, 2018): 177. http://dx.doi.org/10.52964/amja.0728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grigore, Elena, Norman Garrick, Raphael Fuhrer, and Ing Kay W. Axhausen. "Bikeability in Basel." Transportation Research Record: Journal of the Transportation Research Board 2673, no. 6 (April 12, 2019): 607–17. http://dx.doi.org/10.1177/0361198119839982.

Full text
Abstract:
“Bikeability” is becoming increasingly relevant in the field of transport- and urban planning. However, it is often unclear how bikeability is defined, let alone how it can be modeled. The goal of this project was to develop a quantitative method to model bikeability. A case study area in the city of Basel, Switzerland was selected for assessing the model. Here “bikeability” is understood as a measure of the ability and convenience in reaching important destinations by bike, based on the travel distance weighted by the perceived safety, -comfort, and -attractiveness of the streets and intersections along the routes. The underlying assumption was that cyclists try to minimize the distance traveled and maximize the perceived safety, -comfort, and -attractiveness of their route of choice. Unlike most of the previous bikeability assessments we reviewed, our method used existing route choice studies to identify attributes for quantifying cycling quality, which presumably results in a model that more accurately reflects real-life behavior. Many relevant attributes that have not been captured by previous models are included in this work, such as the high curbs of tram stops, tram tracks, and the turn direction at intersections. The method is suitable for several applications in urban planning, such as the identification of locations that need improvement and the comparison of planning measures. The current model covers conventional bikes used by commuting cyclists. However, the method could be used for E-bikes and non-commuting cyclists by applying the appropriate input values.
APA, Harvard, Vancouver, ISO, and other styles
10

Nishimura, Jun-ichi, Antoine Soubret, Simon Buatois, Jean-Eric Charoin, Sasha Sreckovic, Christoph Bucher, Jules Hernández-Sánchez, et al. "An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial." Blood 136, Supplement 1 (November 5, 2020): 2–3. http://dx.doi.org/10.1182/blood-2020-136265.

Full text
Abstract:
Introduction Crovalimab is a novel anti-complement component 5 (C5) monoclonal antibody engineered with the Sequential Monoclonal Antibody Recycling Technology (SMART-Ig; Fukuzawa et al, Sci Rep. 2017) to extend half-life and enable infrequent, subcutaneous (SC) self-administration in C5-mediated diseases. Crovalimab is being investigated as a therapy for paroxysmal nocturnal hemoglobinuria (PNH), a disease for which C5 inhibition is the standard of care. The Phase I/II COMPOSER trial (NCT03157635; Röth, et al. Blood. 2020) is a global, open-label, multicenter study of crovalimab consisting of 4 sequential parts. Parts 1, 2, and 3 assessed the pharmacokinetics (PK) and safety of crovalimab in healthy volunteers, C5 inhibitor-naive patients, and patients switched from eculizumab, respectively. Part 4 assessed an optimized crovalimab dose and regimen in naive and switched patients with PNH. Because eculizumab and crovalimab bind to different C5 epitopes, drug-target-drug complexes (DTDCs) consisting of eculizumab, C5, and crovalimab motifs can temporarily form in the circulation of patients who switch treatments. DTDCs can form in a range of sizes, from single crovalimab-C5-eculizumab motif to larger complexes with multiple motifs. Larger DTDCs are a concern because they take longer to clear and may be more likely to induce type III hypersensitivity reactions. Objectives Describe the impact of DTDC formation on the safety, PK, and pharmacodynamics of crovalimab in patients with PNH who switched from eculizumab to crovalimab and to describe the effect of crovalimab dose on DTDC size distribution and kinetics. Study Design and Methods Using data from COMPOSER Parts 1-3, a biochemical mathematical model was developed to investigate the kinetics of the formation and dissociation of DTDCs under the assumption that larger complexes are formed by the reversible binding of smaller complexes. The model was calibrated using concentration-time profiles of total C5, total crovalimab, and the concentration of eculizumab at the time of crovalimab initiation. DTDC size distributions were measured using size-exclusion chromatography coupled to enzyme-linked immunosorbent assay. Using model-based simulations, an optimized crovalimab dosing strategy was identified to reduce the formation of large DTDCs while maintaining serum concentration of crovalimab above the target level of ≈ 100 μg/mL. The optimized dose and regimen were a loading series of 1000 mg intravenously on day 1 and 340 mg SC on days 2, 8, 15, and 22, followed by maintenance dosing of 680 mg SC every 4 weeks starting on day 29. The loading dose series increased the total crovalimab dose received during the first month of treatment to reduce the formation of larger DTDCs, in line with the lattice theory of complex formation. This optimized dosing strategy was investigated in Part 4 patients who switched from eculizumab. Results In COMPOSER, 19 patients with PNH were enrolled in Part 3 and switched from eculizumab to crovalimab. DTDCs were observed in all patients from Part 3 (Figure; larger DTDCs are found in fractions 1-4 and smaller crovalimab-containing complexes, such as single motifs and single crovalimab molecules, are found in fractions 5 and 6). Two Part 3 patients experienced clinical manifestations compatible with type III hypersensitivity reactions that were ascribed to DTDCs. The DTDC size distribution in Part 4 patients, who received the optimized dosing strategy, evolved differently than in Part 3 patients, consistent with model predictions. In the switched patients from Part 4, large DTDC levels started to decrease on day 8 and continued to decrease, in contrast to Part 3, in which they started to decrease on day 15. On day 22, the mean percentage of the largest DTDCs was reduced by 56% in patients in Part 4 relative to patients in Part 3. Part 4 patients achieved and maintained serum crovalimab concentrations above ≈ 100 µg/mL throughout follow-up. Despite DTDCs being observed in all Part 4 patients who switched from eculizumab, no adverse events suggestive of a type III hypersensitivity reaction occurred. Conclusions The optimized crovalimab regimen resulted in lower concentrations of large DTDCs than in patients who received the Part 3 regimen and reduced the persistence of DTDCs in patients who switched treatment. This regimen is now being evaluated in the Phase III COMMODORE 1 (NCT04432584) and COMMODORE 2 (NCT04434092) studies. Figure Disclosures Nishimura: F. Hoffmann-La Roche Ltd: Consultancy, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Alexion: Honoraria, Research Funding; Chugai: Consultancy. Soubret:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Buatois:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Charoin:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Sreckovic:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Bucher:F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company, Ended employment in the past 24 months, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; ANAVEON AG: Current Employment. Hernández-Sánchez:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Jordan:F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ramos:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Genentech, Inc: Current Employment, Other: Received fellowship support from Genentech, Inc.. Arase:Osaka University: Current Employment; Chugai: Consultancy; Alexion: Research Funding; F. Hoffmann-La Roche. Ltd.: Consultancy, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Hotta:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Isaka:Osaka University: Current Employment; Chugai: Research Funding, Speakers Bureau; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ito:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Kanakura:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Chugai Pharmaceutical: Consultancy. Kim:Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Kinoshita:Alexion: Honoraria; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Morii:F. Hoffmann-La Roche Ltd: Honoraria, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding; Chugai: Honoraria, Research Funding. Panse:Apellis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai: Speakers Bureau; Grunenthal: Consultancy, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Speakers Bureau; Alexion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Peffault De Latour:Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Apellis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Research Funding. Röth:Apellis: Consultancy, Honoraria; Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Research Funding; Biocryst: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria. Schrezenmeier:Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Sica:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding. Takamori:Alexion: Research Funding; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ueda:Chugai: Research Funding; Novartis: Honoraria; Alexion: Consultancy, Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Sanofi: Consultancy, Honoraria. Yoon:Kyowahako Kirin: Research Funding; Novartis: Consultancy, Honoraria; Janssen: Consultancy; F. Hoffmann-La Roche: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding; YuhanPharma: Research Funding; Amgen: Consultancy, Honoraria. Paz-Priel:Genentech, Inc: Current Employment; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Sostelly:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland..
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Rehab Basel (Basel, Switzerland)"

1

Hebeisen, Erika. "Leidenschaftlich fromm die pietistische Bewegung in Basel 1750-1830 /." Köln : Böhlau, 2005. http://catalog.hathitrust.org/api/volumes/oclc/61219074.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Garrington, Jim. "Practicum, apprenticeship a training proposal for the European School for Officers Training, Basel, Switzerland /." Theological Research Exchange Network (TREN), 1988. http://www.tren.com.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Steinbrink, Matthias. "Ulrich Meltinger : ein Basler Kaufmann am Ende des 15. Jahrhunderts." Stuttgart Steiner, 2007. http://bvbr.bib-bvb.de:8991/F?func=service&docl̲ibrary=BVB01&docn̲umber=016221926&linen̲umber=0001&funcc̲ode=DBR̲ECORDS&servicet̲ype=MEDIA.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abreu, Sara Andreia Rodrigues. "Dietary assessment of the western Lowland gorilla (Gorilla gorilla gorilla) group in Zoo Basel, Switzerland." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2016. http://hdl.handle.net/10400.5/12002.

Full text
Abstract:
Dissertação de Mestrado Integrado em Medicina Veterinária
While free-ranging gorilla populations are declining, captive gorillas face serious health issues such as obesity and heart disease. A proper dietary management is crucial to maintain healthy and thriving populations, but in captivity it can be difficult to provide diets that are both nutritionally and functionally equivalent to wild diets. During this study in Zoo Basel were evaluated two male gorillas, one silverback (16 years) and one blackback (12 years), two late-stage pregnant females (25 and 32 years) and two geriatric females (47 and 55 years). Diet adequacy was assessed through the analysis of the diet composition, individual nutrient intake, dietary enrichment program, anthropometric features and previous clinical records. Overall, the diet offered at Zoo Basel was complete and mostly adequate to the gorillas’ behavioural and nutritional needs. Some significant differences were observed between individual diets, linked to management options, individual preferences and physiologic, ageor hierarchy-related specific requirements. A list of recommendations was compiled and a sample diet was created to help correct the identified nutrient imbalances. An integrated individual analysis of diet adequacy is particularly important in a species like the gorilla, due to its complex social interactions and the need to group-feed to maintain proper levels of welfare.
RESUMO - Enquanto a população de gorilas selvagens diminui, os que estão em cativeiro deparam-se com graves problemas de saúde como a obesidade e a doença cardíaca. Uma dieta adequada é essencial para manter estas populações saudáveis, mas em cativeiro é difícil oferecer dietas nutricionalmente e funcionalmente análogas às naturais. Durante este estudo, no Jardim Zoológico da Basileia, foram avaliados dois gorilas machos, de dorso-prateado (16 anos) e de dorso-negro (12 anos), duas fêmeas em final de gestação (25 e 32 anos) e duas fêmeas geriátricas (47 e 55 anos). A adequação da dieta foi avaliada através da análise da sua composição, do consumo individual de nutrientes, do programa de enriquecimento ambiental, das características antropométricas e de registos clínicos prévios. No geral, a dieta fornecida foi completa e adequada às necessidades comportamentais e nutricionais dos gorilas. Foram observadas algumas diferenças significativas entre indivíduos, ligadas a opções de maneio, preferências individuais e requisitos específicos do estado fisiológico, idade ou hierarquia. Foi elaborada uma lista de recomendações e criada uma dieta-amostra para ajudar a corrigir os desequilíbrios identificados. Uma análise dietética integrada e individual é particularmente importante numa espécie como o gorila, devido às suas complexas interações sociais e à necessidade de serem alimentados em grupo para manter níveis adequados de bem-estar.
APA, Harvard, Vancouver, ISO, and other styles
5

Makwiramiti, Anthony Munyaradzi. "The implementation of the new capital accord (BASEL II) : a comparative study of South Africa, Switzerland, Brazil and the United States." Thesis, Rhodes University, 2009. http://hdl.handle.net/10962/d1002717.

Full text
Abstract:
The international banking environment has become potentially riskier because of the recent developments in financial services and products which have changed the way banks do their day to day business. Imposing minimum capital adequacy regulations is one way of fostering stability in the global banking system. A number of countries have started to implement the new capital adequacy rules (Basel II) following the worldwide consensus among central bankers that bank‟s capital levels should be regulated to enhance global financial stability. In this study, through the comparative analysis of the general implementation issues it was established that emerging countries apply all Basel II rules uniformly across all the banking institutions that operate in their territories. Developed countries apply these rules only to large and internationally active banks and because of the diversity of their banking industries, they also apply domestically modified rules to the domestically based banks. For the successful implementation of Basel II, properly planning, devoting bank resources and making necessary legislative amendments are prerequisites for incorporating Basel II into the regulatory framework for any country. The study concludes that the current global financial turmoil continues to pose a threat to the effectiveness of the Basel II rules which are aimed at achieving global financial stability.
APA, Harvard, Vancouver, ISO, and other styles
6

Schneider, Ulrich Johannes. "Martin Stuber, Stefan Hächler and Luc Lienhard (eds), Hallers Netz. Ein europäischer Gelehrtenbriefwechsel zur Zeit der Aufklärung, Basel 2005 (Rezension)." Universitätsbibliothek Leipzig, 2015. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-161442.

Full text
Abstract:
Haller was, by any standard, a very prolific writer, not only of letters. He published 24 books in 50 volumes, many of which he reworked for second editions; he wrote 450 essays, 9000 book reviews, and edited another 52 volumes. Of his letters exchanged with 1139 male and 50 female correspondents, close to 17,000 have survived.
APA, Harvard, Vancouver, ISO, and other styles
7

Schneider, Ulrich Johannes. "Martin Stuber, Stefan Hächler and Luc Lienhard (eds), Hallers Netz. Ein europäischer Gelehrtenbriefwechsel zur Zeit der Aufklärung, Basel 2005 (Rezension)." Cambridge Univ. Press, 2008. https://ul.qucosa.de/id/qucosa%3A13184.

Full text
Abstract:
Haller was, by any standard, a very prolific writer, not only of letters. He published 24 books in 50 volumes, many of which he reworked for second editions; he wrote 450 essays, 9000 book reviews, and edited another 52 volumes. Of his letters exchanged with 1139 male and 50 female correspondents, close to 17,000 have survived.
APA, Harvard, Vancouver, ISO, and other styles
8

Ferry, Matthieu Alexis. "Adaption of the paleoseismological approach to local tectonic regime: comparative study of the intraplate Basel-Reinach fault, Switzerland and the interplate North Anatolian fault, Turkey /." Zürich : ETH, 2004. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=15537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kallstenius, Marie-Louise. "Läkande rum : - ett examensarbete om arkitektur, psykiatri och läkande miljöer." Thesis, KTH, Arkitektur, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-72634.

Full text
Abstract:
Projektets syfte är att försöka utröna hur en visionär psykiatri skulle kunna se ut i framtiden. Jag frågade mig om man som arkitekt kan komma med en vision som är en lösning på psykiatrins problem. Hur gör man för att maximera de läkande faktorerna så att patienter återhämtar sig så fort och fullständigt som möjligt? Projektet är också ett försök att förmänskliga en av de stora insitutioner vi är beroende av i samhället och har resulterat i en bok i ämnet och ett designprojekt.
APA, Harvard, Vancouver, ISO, and other styles
10

Makwiramiti, Anthony Munyaradzi. "The implementation of the new capital accord (BASEL II) : a comparative study of South Africa, Switzerland, Brazil and the United States /." 2008. http://eprints.ru.ac.za/1607/.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Rehab Basel (Basel, Switzerland)"

1

Furer, René. Herzog & de Meuron, Rehab Burgfeld: Baukunst als Humanismus : ein Besuch im Zentrum für Querschnittgelähmte und Hirnverletzte in Basel. Benglen: R. Furer, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Heiko, Hrsg :. Haumann, ed. Acht Jahrhunderte Juden in Basel: 200 Jahre Israelitische Gemeinde Basel. Basel: Schwabe & Co. AG Basel, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Paul Sacher Stiftung (Basel, Switzerland). Paul Sacher Stiftung Basel. Basel: Die Stiftung, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1945-, Haumann Heiko, ed. Acht Jahrhunderte Juden in Basel: 200 Jahre Israelitische Gemeinde Basel. Basel: Schwabe, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Antikenmuseum und Sammlung Ludwig (Basel, Switzerland). Antikenmuseum Basel und Sammlung Ludwig. [Genf, Switzerland]: Paribas (Suisse) SA in Zusammenarbeit mit dem Schweizerischen Institut für Kunstwissenschaft, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1913-, Craig Gordon Alexander, and Gossman Lionel, eds. Geneva, Zurich, Basel: History, culture & national identity. Princeton, N.J: Princeton University Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Die Diözesankonferenz des Bistums Basel. Freiburg, Schweiz: Universitätsverlag, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Switzerland) International Art Fair (20th 2020 Basel. Year 50: Art/Basel. Edited by Dirié Clément editor, Gavillet Gilles editor, Spiegler Marc editor, Manchester Clare editor, and Manchester Elizabeth editor. Geneva: JPR Editions, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hofmann, Paul. Switzerland: The smart traveler's guide to Zurich, Basel, and Geneva. New York: H. Holt, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Eugen, Keller, and Wirth Franz, eds. 100 Jahre Pfarrei St. Joseph Basel. [Basel]: Christoph Merian Verlag, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Rehab Basel (Basel, Switzerland)"

1

Vinken, Gerhard. "6 Basel / Switzerland." In Zones of Tradition - Places of Identity, 83–96. Bielefeld, Germany: transcript Verlag, 2021. http://dx.doi.org/10.14361/9783839454466-006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Etter, Walter, Michael Knappertsbusch, and Loïc Costeur. "BASEL: The Natural History Museum Basel (NMB)." In Paleontological Collections of Germany, Austria and Switzerland, 27–38. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-77401-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Block, Elaine C. "Medieval Choir Stalls in Basel, Switzerland: Short Guide." In Profane Arts of the Middle Ages, 137–46. Turnhout: Brepols Publishers, 2010. http://dx.doi.org/10.1484/m.pama-eb.4.3011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Debrunner, Gabriela. "Selecting Switzerland." In The Business of Densification, 87–116. Cham: Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-49014-9_4.

Full text
Abstract:
AbstractThe study design of this book is based on four case studies located in Switzerland: the four cities—Zurich, Basel, Köniz, and Kloten—where a concrete densification area is analyzed. Through this case study design, objectives of broadness of scope and analytical depth are reached. Chapter 4 entangles what is specific to each case study and which observations are of broader significance. First, the Swiss context of the empirical analysis is described, then the detailed reasons for case selection, as well as the different data collection and analysis methods applied. Lastly, this chapter is concluded by reflecting upon the researcher’s own positionality in the research process and the various challenges encountered in the field.
APA, Harvard, Vancouver, ISO, and other styles
5

Ratschiller Nasim, Linda Maria. "The Religious Space of Knowledge: The Basel Mission, Worldwide Webs and Pietist Purity." In Cambridge Imperial and Post-Colonial Studies, 49–103. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-27128-1_2.

Full text
Abstract:
AbstractThis chapter examines the ideological and social context in which the Basel Mission emerged and scrutinises the changing meaning of Pietist purity over the nineteenth century. The Basel Mission drew upon the support of wealthy and powerful patrician families from Basel and far-flung Pietist networks across Europe and beyond. However, it swiftly transformed into a grassroots movement, funded by small donations from a large number of people in urban and rural areas of Switzerland and Germany. The Basel Mission’s evangelising efforts abroad were linked to charitable activities at home, which tackled the ostensible problem of de-Christianisation within Europe and fundamentally depended on voluntary work, especially by women and children. Although healing had been part of Pietism ever since the movement gained momentum, most adherents had reservations about the morality and efficacy of scientific medicine, discernible in their preference for healing and deliverance theology. The Basel missionaries’ prolonged experience of death and illness in West Africa, however, allowed for the reformulation of Pietist concepts of purity and healing through the integration of scientific theories of disease and hygiene.
APA, Harvard, Vancouver, ISO, and other styles
6

Stotz, Peter. "Chapter 5. Switzerland." In Comparative History of Literatures in European Languages, 121–34. Amsterdam: John Benjamins Publishing Company, 2024. http://dx.doi.org/10.1075/chlel.xxxiv.05sto.

Full text
Abstract:
The territory now known as Switzerland was a contact zone for a range of ethnicities, linguistic areas and literary influences. There was no such thing as a specifically Swiss literary landscape in the Latin Middle Ages. Nor did the first beginnings of the formation of a state come into view until the late Middle Ages. In the western areas, significant influence from Gaul/France can be detected. The south-east belongs to the Rhaeto-Romance cultural area. In the east, settled by the Alemanni, the environs of Lake Constance, with the abbeys of St. Gall and Reichenau, were highly productive. Basel was oriented towards the north and the Upper Rhine. Literature was first produced in monasteries and bishoprics, later increasingly in towns. The most popular genres were hagiography and regional historiography, followed by spiritual poetry, theological and profane literature, and didactic poetry.
APA, Harvard, Vancouver, ISO, and other styles
7

Epting, Jannis, Matteo Baralis, Rouven Künze, Matthias H. Mueller, Alessandra Insana, Marco Barla, and Peter Huggenberger. "Thermal Activation of Tunnel Infrastructures: City-Scale Solutions for Basel, Switzerland." In Challenges and Innovations in Geomechanics, 993–1001. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64518-2_118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grossmann, Flavia. "Social Assistance and Self-Organised Interest Groups: The Counselling Centre for Foreign Workers and Italian Educational Institutions in Basel-City (1960s–1980s)." In Switzerland and Migration, 229–48. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-94247-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zuppinger, Urs, and Peter Knoepfel. "Swiss Border Incident: A Case Study of the Ciba-Geigy Special Waste Incineration Plant in Basel, Switzerland." In The Waste and the Backyard, 117–59. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-015-9107-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Basel (Switzerland)." In Northern Europe, 75–79. Routledge, 2013. http://dx.doi.org/10.4324/9780203059159-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Rehab Basel (Basel, Switzerland)"

1

Fischer, Susanne. "Climate Adaption and Urban Planning - The Case of Basel, Switzerland." In 58th ISOCARP World Planning Congress . ISOCARP, 2022. http://dx.doi.org/10.47472/n5sjjpwb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kumano, Yusuke, Hiroshi Asanuma, Akito Hotta, Hiroaki Niitsuma, Ulrich Schanz, and Markus Häring. "Reservoir structure delineation by microseismic multiplet analysis at Basel, Switzerland, 2006." In SEG Technical Program Expanded Abstracts 2007. Society of Exploration Geophysicists, 2007. http://dx.doi.org/10.1190/1.2792735.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mukuhira, Yusuke, Hiroshi Asanuma, and Markus Häring. "Study on trigger mechanism of large induced seismicity at a hydraulic stimulation in Basel, Switzerland." In Proceedings of the 11th SEGJ International Symposium, Yokohama, Japan, 18-21 November 2013. Society of Exploration Geophysicists, 2013. http://dx.doi.org/10.1190/segj112013-053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jaeger, Peter. "Conversion of Three Crude Oil Tanks into Liquid Bitumen Storage Tanks at Auhafen, Basel, Switzerland." In IABSE Congress, Stockholm 2016: Challenges in Design and Construction of an Innovative and Sustainable Built Environment. Zurich, Switzerland: International Association for Bridge and Structural Engineering (IABSE), 2016. http://dx.doi.org/10.2749/stockholm.2016.1761.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Feigenwinter, Christian, Eberhard Parlow, Roland Vogt, Michael Schmutz, Nektarios Chrysoulakis, Fredrik Lindberg, Mattia Marconcini, and Fabio del Frate. "Spatial distribution of sensible and latent heat flux in the URBANFLUXES case study city Basel (Switzerland)." In 2017 Joint Urban Remote Sensing Event (JURSE). IEEE, 2017. http://dx.doi.org/10.1109/jurse.2017.7924594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Asanuma, Hiroshi, Yusuke Kumano, Hirokazu Moriya, Hiroaki Niitsuma, Ulrich Schanz, and Markus Häring. "Identification of microseismic multiplets in the frequency domain and interpretation of reservoir structure at Basel, Switzerland." In SEG Technical Program Expanded Abstracts 2008. Society of Exploration Geophysicists, 2008. http://dx.doi.org/10.1190/1.3059187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Krompák, Edina. "Diglossia and Local Identity: Swiss German in the Linguistic Landscape of Kleinbasel." In GLOCAL Conference on Asian Linguistic Anthropology 2019. The GLOCAL Unit, SOAS University of London, 2019. http://dx.doi.org/10.47298/cala2019.7-2.

Full text
Abstract:
The city of Basel is situated in the German-speaking part of Switzerland, in the geographic triangle of three countries: France, Germany and Switzerland. Everyday urban life is characterised by the presence of Standard German and Swiss German as well as diverse migrant languages. Swiss German is ‘an umbrella term for several Alemannic dialects’ (Stepkowska 2012, 202) which differ from Standard German in terms of phonetics, semantics, lexis, and grammar and has no standard written form. Swiss German is predominantly used in oral forms, and Standard German in written communication. Furthermore, an amalgamation of bilingualism and diglossia (Stepkowska 2012, 208) distinguishes the specific linguistic situation, which indicates amongst other things the high prestige of Swiss German in everyday life. To explore the visibility and vitality of Swiss German in the public display of written language, we examined the linguistic landscape of a superdiverse neighbourhood of Basel, and investigated language power and the story beyond the sign – ‘stories about the cultural, historical, political and social backgrounds of a certain space’ (Blommaert 2013, 41). Our exploration was guided by the question: How do linguistic artefacts – such as official, commercial, and private signs – represent the diglossic situation and the relation between language and identity in Kleinbasel? Based on a longitudinal ethnographic study, a corpus was compiled comprising 300 digital images of written artefacts in Kleinbasel. Participant observation and focus group discussions about particular images were conducted and analysed using grounded theory (Charmaz 2006) and visual ethnography (Pink 2006). In our paper, we focus on signs in Swiss German and focus group discussions on these images. Initial analyses have produced two surprising findings; firstly, the visibility and the perception of Swiss German as a marker of local identity; secondly, the specific context of their display.
APA, Harvard, Vancouver, ISO, and other styles
8

Stampfli, J. R., R. Lazar, M. Spitschan, B. Schrader, C. di Battista, R. Häfliger, O. Schälli, et al. "THE LIGHT-DOSIMETER – A NEW DEVICE TO HELP ADVANCE RESEARCH ON THE NON-VISUAL RESPONSES TO LIGHT." In CIE 2021 Conference. International Commission on Illumination, CIE, 2021. http://dx.doi.org/10.25039/x48.2021.op18.

Full text
Abstract:
Research on the non-visual responses to light under real-world conditions has been hindered by the lack of suitable measuring devices. Here, we present a novel, portable and miniaturised light-dosimeter attached to a spectacle frame, taking measurements in the near-corneal plane. The recorded data is processed with the help of the custom-made software package Lido Studio. In addition to commonly used metrics such as illuminance and correlated colour temperature (CCT), it also provides metrics standardised in CIE S 026:2018. Data can be analysed directly in Lido Studio or exported as a PDF report or a comma-separated values (CSV) file for further in-depth time-series analyses. The Federal Institute of Metrology (METAS) optics laboratory (Bern-Wabern, Switzerland) assessed the light-dosimeter’s spectral and geometric properties. Subsequentially, the team at the Centre for Chronobiology (Basel, Switzerland) confirmed that measurements performed with a light-dosimeter were comparable to those from a commercial spectroradiometer.
APA, Harvard, Vancouver, ISO, and other styles
9

Moein, M., B. Valley, and M. Ziegler. "Preliminary fractal analysis of fracture spacing inferred from an acoustic televiewer log run in the Basel-1 geothermal well (Switzerland)." In The 2016 Isrm International Symposium, Eurock 2016. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2016. http://dx.doi.org/10.1201/9781315388502-192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gonzalez-Diaz, Humbert, Marianne Garber, Alexander Tropsha, Francoise Dumas, Jerzy Leszczynski, Maria Natália D. S. Cordeiro, Jia Zhou, et al. "MOL2NET-07, Conference on Molecular, Biomedical, and Computational Sciences and Engineering, ISSN: 2624-5078, MDPI SciForum, Basel, Switzerland, 2021, 7th ed." In MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/mol2net-07-09232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Rehab Basel (Basel, Switzerland)' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography